OGN
Organon & Co. · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -21.4% ·
share flow -19.7% ·
net new positions -20.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 112 | -5 | 127.57M | $1.69B | +9 | −13 |
| Q1 2026 | 119 | +3 | 138.29M | $828.86M | +8 | −6 |
| Q4 2025 | 116 | 0 | 159.06M | $1.14B | +2 | −1 |
| Q3 2025 | 19 | +2 | 102.90M | $1.10B | +2 | −1 |
| Q2 2025 | 15 | +2 | 101.45M | $982.02M | +3 | −1 |
| Q1 2025 | 10 | -1 | 22.51M | $334.60M | — | −1 |
| Q4 2024 | 11 | -3 | 17.81M | $265.62M | — | −3 |
| Q3 2024 | 13 | +3 | 12.85M | $245.79M | +4 | −1 |
| Q2 2024 | 10 | — | 11.89M | $246.22M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 9.34M | — | $139.33M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 4.26M | +0.3% | $63.58M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 4.26M | +0.3% | $63.58M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 1.69M | +12.9% | $25.26M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 1.44M | -41.7% | $21.32M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 1.44M | -41.7% | $21.32M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 1.44M | -41.7% | $21.32M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 1.44M | -41.7% | $21.32M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Gotham Asset Management ✦ | 803.31K | +0.2% | $11.99M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 178.29K | +9.2% | $2.66M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 178.29K | +9.2% | $2.66M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Wellington Management ✦ | 32.97K | +44.2% | $491,853 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Marshall Wace ✦ | 28.98K | -48.7% | $432,307 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Marshall Wace ✦ | 28.98K | -48.7% | $432,307 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Millennium Management ✦ | 18.92K | -79.4% | $282,227 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Bridgewater Associates ✦ | 18.05K | -91.1% | $269,261 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 352 | -100.0% | $5,252 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Renaissance Technologies | $4.59M | was 0.0% |
| D. E. Shaw & Co. | $2.69M | was 0.0% |
| Arrowstreet Capital | $396,718 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 604 holders, 199.08M shares, $1.18B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.